Health News Releases

  • Today May 20
October 11, 2016 17:25
Zymergen Announces $130 Million in Series B Funding, Led by SoftBank
Zymergen, a technology company unlocking the power of biology, announced today that it has raised 130 million USD in Series B funding led by SoftBank Group (TOKYO: 9984). The round also includes prior
October 11, 2016 10:50
Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m
Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody®-based therapeutics, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced a global, strategic, mu
October 11, 2016 10:45
Durvalumab Shows Promising Preliminary Early Data in Lung and Head & Neck Cancers
AstraZeneca and its global biologics research and development arm, MedImmune, announced today efficacy and safety data for durvalumab from two separate cohorts of patients with either advanced non-sma
October 10, 2016 09:30
Faslodex Demonstrates Progression-Free Survival Advantage in 1st Line Advanced Breast Cancer
AstraZeneca today announced data from the Phase III FALCON trial demonstrating superior median progression-free survival (PFS) for Faslodex (fulvestrant) 500mg compared to Arimidex (anastrozole) 1mg i
October 07, 2016 13:55
Masimo Announces CE Marking of Rad-97™ Pulse CO-Oximeter®
Masimo (NASDAQ: MASI) announced today the CE marking of the Rad-97™ Pulse CO-Oximeter®. Rad-97 offers the same Measure-through Motion and Low Perfusion™ SET® pulse oximetry and upgradeable rainbow SET
October 06, 2016 15:35
Herbalife Nutrition Asia Pacific Survey Reveals That Millennials Find It Difficult to Engage in Physical Activities in the Modern Workplace
Herbalife Nutrition, a global nutrition company, has released findings from its Asia Pacific Millennials At Work Survey[1], showing that younger workers in Asia want to do more physical exercise while
October 05, 2016 18:00
Cardinal Health Expands in Asia
Leading global, integrated healthcare services and products company, Cardinal Health (NYSE:CAH), today announced that it will bring its powder-free gloves product line to Hong Kong while further penet
October 05, 2016 16:00
IncellDx’s Quantitative Immuno-Oncology Assay OncoTect iO Published in New Study
IncellDx, Inc., a single cell, precision medicine company, today announced that the international peer-reviewed medical journal Cancer Immunology, Immunotherapy has published a manuscript entitled: “Q
October 04, 2016 21:00
Replicor to Disclose Late Breaking HBV Clinical Data at AASLD 2016
Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that the preliminary interim analysis from its latest REP 401 clinica
October 04, 2016 13:50
QuintilesIMS: Merger Creates a Leading Global Integrated Information and Technology-Enabled Healthcare Service Provider
Quintiles IMS Holdings, Inc. (NYSE:Q) today announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdi
October 04, 2016 11:45
Samsung Bioepis' Marketing Authorization Application for SB3 Trastuzumab Biosimilar Candidate Accepted for Review by the European Medicines Agency
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Application (MAA) for SB3, a biosimilar candidate refer
September 30, 2016 09:45
Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies
Boehringer Ingelheim and Sarah Cannon Research Institute, the research arm of Sarah Cannon, the global cancer institute of HCA, announced today a new strategic collaboration. This partnership brings t
September 29, 2016 11:50
Boehringer Ingelheim Boosts Immune-Oncology Pipeline Through Collaboration with ViraTherapeutics
Boehringer Ingelheim and ViraTherapeutics today announced a long term collaboration to jointly develop a next generation oncolytic virus therapy platform and to investigate ViraTherapeutic’s lead cand
September 27, 2016 13:35
Herbalife Nutrition and Special Olympics Announce $1 Million Fitness Collaboration
Herbalife (NYSE: HLF), a global nutrition company, today announced a $1 million collaboration with Special Olympics to support the organization’s fitness programming around the world, focusing on incr
September 23, 2016 19:30
Alexion Employees Volunteer Together in Company’s First Global Day of Service
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that more than 1,500 employees around the world are volunteering in their respective communities as part of the Company’s first Global Day o
September 22, 2016 13:40
SAB Biotherapeutics' Immunotherapy Proposal among Top Platform Technology Solutions in WHO Report
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, announced today that its DiversitAb human antibody production platform, leveraging transchromosomic cattle (Tc Bovine
September 21, 2016 16:00
Smith & Nephew Reinforces Strong Educational Commitment to Advanced Wound Management at World Union of Wound Healing Societies Meeting (WUWHS)
Smith & Nephew (LSE:SN) (NYSE:SNN), the global medical technology business, highlights three scientific symposia at World Union of Wound Health Societies (WUWHS) on 25-29 September 2016 in Florence, I
September 21, 2016 14:00
Takeda and Zydus Cadila partner to address the global threat of Chikungunya
Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) and Zydus Cadila today announced a partnership to tackle chikungunya, an emerging infectious disease in Africa, Asia and the Indian subcon
September 21, 2016 13:50
New survey reveals 9 out of 10 patients with IPF were happy with how their doctor told them about their IPF diagnosis
A diagnosis of IPF is news that few patients want to hear from their physician, but the reality is that approximately 3 million people worldwide are living with idiopathic pulmonary fibrosis (IPF). It
September 21, 2016 01:00
One-Year Results in Japanese Clinical Study Affirms the GORE® VIABAHN® Endoprosthesis as a Device-of-Choice for Treating Complex SFA Disease
W. L. Gore & Associates, Inc. (Gore) today announced positive results from a prospective, multicenter Investigational Device Exemption (IDE) Clinical Study of the GORE® VIABAHN® Endoprosthesis with He
September 20, 2016 18:45
First Implant Completed in Pivotal Study of GORE® TAG® Thoracic Branch Endoprosthesis
W. L. Gore & Associates, Inc. (Gore) today announced the first implant of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE) in the pivotal study. The patient was enrolled by Himanshu Patel, MD, sect
September 20, 2016 10:55
Biopharmaceutical Industry Calls the Recommendations of UN High Level Panel on Access to Medicines a Missed Opportunity to Genuinely Address Patients’ Needs
The biopharmaceutical industry believes the UN High Level Panel on Access to Medicines (HLP) lent an unprecedented opportunity to address critical issues affecting the ability of millions of people in
September 19, 2016 10:25
Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from the 96-week blinded extension period (for a total of up to 120 weeks of exposur
September 19, 2016 10:15
Glyxambi® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European Union
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of Glyxambi® (empagliflozin/linagliptin) for use in adults with type 2 d
September 19, 2016 10:10
Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLARO™ (ixazomib), the First Oral Proteasome Inhibitor, for Use in Patients with Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recom
25 per page50 per page75 per page100 per page